MedTrace Logo

Allogeneic Stem Cell Transplantation for the Treatment of Multiple Sclerosis (Compassionate Use)

NCT02084121 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2022-07-18

No results posted yet for this study

Summary

A subject was treated under compassionate use provisions under this study with facilitating cell therapy (FCRx) product manufactured using the CliniMACS (Miltenyi Biotec) device, rather than the Max Sep (Baxter) device.

Conditions

  • Metachromatic Leukodystrophy

Interventions

BIOLOGICAL

Enriched Hematopoetic Stem Cell Infusion

Enriched Hematopoetic Stem Cell Infusion

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • Talaris Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Joanne Kurtzberg, MD · Duke University

Eligibility

Min Age
3 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02084121 on ClinicalTrials.gov